Recently, 《Life Sciences Review APAC》, an international pharmaceutical industry media outlet, announced its annual selections. AsymBio was exclusively named “Integrated Biologics CDMO Company of the Year in APAC 2026", on the strength of its globally leading one-stop integrated biologics CDMO services, and was also named among the "Top CDMO in APAC" list-further reinforcing AsymBio's benchmark position in Asia-Pacific biologics R&D and manufacturing services.
《Life Sciences Review APAC 》(print ISSN 2831-8323 | digital ISSN 2831-8331) is an industry magazine focused on the Asia-Pacific life sciences sector. Its awards are a highly credible and prestigious honor in the Asia-Pacific biopharmaceutical industry, recognizing leading enterprises that demonstrate excellence in technological innovation, capacity and scale, regulatory compliance, commercial delivery, and industry influence.
In an exclusive interview with 《Life Sciences Review APAC 》, Rui Yang, CEO of AsymBio, stated:
"Leveraging our integrated CDMO service model and AccPCC early-stage R&D acceleration platform, we take a holistic approach to forward-looking pipeline planning and advanced technologies, project timelines and risk management, and critical milestones on the path to commercialization. By supporting programs throughout the biologics development lifecycle, we help clients accelerate clinical progression and advance toward successful commercialization."
Leveraging the synergistic advantages of the group, AsymBio has built an end-to-end, one-stop biologics CDMO service covering the full value chain of next-generation biologics—from antibodies and bispecific antibodies to ADCs—spanning candidate molecule assessment, process development, sample production, and regulatory filing.
Through the AccPCC early-stage research platform, we bridge early-stage research, non-clinical, and clinical development. Our dual-site manufacturing layout in Jinshan and Fengxian, Shanghai, provides dual capacity to meet demands ranging from early-stage R&D, toxicology batches, and clinical samples to commercial-scale manufacturing. This integrated service system mitigates project risks and timeline delays associated with multi-vendor handovers. Our quality management system complies with global regulatory requirements including NMPA, FDA, and EMA. More importantly, whether for early-stage research services or CDMO services, all project intellectual property rights are fully retained by the client.
This recognition spurs AsymBio onward. Looking ahead, AsymBio will continue to fortify its integrated technology platform and capacity system, deepen its focus on the development and manufacturing of next-generation biologics, empower global innovative pharmaceutical companies, and accelerate the R&D-to-clinic translation of cutting-edge biologics—so that innovative therapies can reach patients worldwide at the earliest possible time.
